Skip to main content
Top
Published in:

Open Access 09-08-2023 | Kidney Cancer | CLINICAL GUIDES IN ONCOLOGY

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

Authors: María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba

Published in: Clinical and Translational Oncology | Issue 9/2023

Login to get access

Abstract

Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma accompanied by recommendations with new evidence and treatment algorithms. A new pathologic classification of RCC by the World Health Organization (WHO) was published in 2022 and this classification would be considered a “bridge” to a future molecular classification. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. Adjuvant treatment with pembrolizumab is an option for intermediate-or high-risk cases, as well as patients after complete resection of metastatic disease. More data are needed in the future, including positive overall survival data. Clinical prognostic classification, preferably IMDC, should be used for treatment decision making in mRCC. Cytoreductive nephrectomy should not be deemed mandatory in individuals with intermediate-poor IMDC/MSKCC risk who require systemic therapy. Metastasectomy can be contemplated in selected subjects with a limited number of metastases or long metachronous disease-free interval. For the population of patients with metastatic ccRCC as a whole, the combination of pembrolizumab–axitinib, nivolumab–cabozantinib, or pembrolizumab–lenvatinib can be considered as the first option based on the benefit obtained in OS versus sunitinib. In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib. As for individuals with advanced RCC previously treated with one or two antiangiogenic tyrosine-kinase inhibitors, nivolumab and cabozantinib are the options of choice. When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.
Literature
2.
4.
go back to reference Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5): e035938.PubMedPubMedCentralCrossRef Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5): e035938.PubMedPubMedCentralCrossRef
5.
go back to reference Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4):135–40.PubMedCrossRef Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4):135–40.PubMedCrossRef
6.
go back to reference Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1–11.PubMedCrossRef Sacco E, Pinto F, Sasso F, Racioppi M, Gulino G, Volpe A, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1–11.PubMedCrossRef
7.
go back to reference Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–7.PubMedCrossRef Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014;32:431–7.PubMedCrossRef
8.
go back to reference Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008;71(2):278–82.PubMedCrossRef Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology. 2008;71(2):278–82.PubMedCrossRef
9.
10.
go back to reference Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM. Small (<or = 3 cm) renal masses: detection with CT versus US and pathologic correlation. Radiology. 1996;198(3):785–8.PubMedCrossRef Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM. Small (<or = 3 cm) renal masses: detection with CT versus US and pathologic correlation. Radiology. 1996;198(3):785–8.PubMedCrossRef
11.
go back to reference Tatar G, Alçin G, Samanci NS, Fenercioglu OE, Beyhan E, Çermik TF. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy. Nucl Med Commun. 2022;43(6):701–9.PubMedCrossRef Tatar G, Alçin G, Samanci NS, Fenercioglu OE, Beyhan E, Çermik TF. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy. Nucl Med Commun. 2022;43(6):701–9.PubMedCrossRef
13.
go back to reference Voss J, Drake T, Matthews H, Jenkins J, Tang S, Doherty J, et al. Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. BJU Int. 2020;125:561–7.PubMedCrossRef Voss J, Drake T, Matthews H, Jenkins J, Tang S, Doherty J, et al. Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. BJU Int. 2020;125:561–7.PubMedCrossRef
14.
go back to reference Koga S, Tsuda S, Nishikido M, Ogawa Y, Hayashi T, Kanetake H. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol. 2001;166:2126.PubMedCrossRef Koga S, Tsuda S, Nishikido M, Ogawa Y, Hayashi T, Kanetake H. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol. 2001;166:2126.PubMedCrossRef
15.
go back to reference Jena R, Narain TA, Singh UP, Srivastava A. Role of Positron Emission Tomography/computed tomography in the evaluation of renal cell carcinoma. Indian J Urol. 2021;37:125–32.PubMedPubMedCentralCrossRef Jena R, Narain TA, Singh UP, Srivastava A. Role of Positron Emission Tomography/computed tomography in the evaluation of renal cell carcinoma. Indian J Urol. 2021;37:125–32.PubMedPubMedCentralCrossRef
17.
go back to reference Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299–311.PubMedPubMedCentralCrossRef Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299–311.PubMedPubMedCentralCrossRef
18.
go back to reference Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta- analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69:660–73.PubMedCrossRef Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta- analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69:660–73.PubMedCrossRef
19.
go back to reference Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 Update. Eur Uroly. 2022;82(2022):399–410.CrossRef Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 Update. Eur Uroly. 2022;82(2022):399–410.CrossRef
20.
go back to reference Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706–20.PubMedCrossRef Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706–20.PubMedCrossRef
21.
go back to reference Brierley JD, Gospodarowicz M, Wittekind C, editors. UICC TNM classification of malignant tumours. 8th ed. New York: Wiley Black-well; 2016. Brierley JD, Gospodarowicz M, Wittekind C, editors. UICC TNM classification of malignant tumours. 8th ed. New York: Wiley Black-well; 2016.
22.
go back to reference Delahunt B, Eble JN, Samaratunga H, Thunders M, Yaxley JW, Egevad L. Staging of renal cell carcinoma: current progress and potential advances. Pathology. 2021;53(1):120–8.PubMedCrossRef Delahunt B, Eble JN, Samaratunga H, Thunders M, Yaxley JW, Egevad L. Staging of renal cell carcinoma: current progress and potential advances. Pathology. 2021;53(1):120–8.PubMedCrossRef
24.
go back to reference WHO. Classification of tumours of the urinary system and male genital organs. 5th ed. Lyon: International Agency for Research on Cancer; 2022. WHO. Classification of tumours of the urinary system and male genital organs. 5th ed. Lyon: International Agency for Research on Cancer; 2022.
25.
go back to reference Netto GJ, Amin MB, Berney BM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022;82(5):469–82.PubMedCrossRef Netto GJ, Amin MB, Berney BM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022;82(5):469–82.PubMedCrossRef
26.
go back to reference Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160: 103287.PubMedCrossRef Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160: 103287.PubMedCrossRef
27.
go back to reference Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, et al. Update in collecting duct carcinoma: current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022;12: 970199.PubMedPubMedCentralCrossRef Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, et al. Update in collecting duct carcinoma: current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 2022;12: 970199.PubMedPubMedCentralCrossRef
28.
go back to reference Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17(12):659–78.PubMedPubMedCentralCrossRef Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17(12):659–78.PubMedPubMedCentralCrossRef
29.
go back to reference Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435–51.PubMedCrossRef Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435–51.PubMedCrossRef
30.
go back to reference Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313–26.PubMedPubMedCentralCrossRef Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313–26.PubMedPubMedCentralCrossRef
31.
go back to reference Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52.PubMedCrossRef Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–52.PubMedCrossRef
32.
go back to reference MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TBL, Hilvano-Cabungcal AM, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012;61(5):972–93.PubMedCrossRef MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TBL, Hilvano-Cabungcal AM, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012;61(5):972–93.PubMedCrossRef
33.
go back to reference Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016;196(4):989–99.PubMedPubMedCentralCrossRef Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016;196(4):989–99.PubMedPubMedCentralCrossRef
34.
go back to reference Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, et al. Role of active surveillance for localized small renal masses. Eur Urol Oncol agosto de. 2018;1(3):177–87.CrossRef Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, et al. Role of active surveillance for localized small renal masses. Eur Urol Oncol agosto de. 2018;1(3):177–87.CrossRef
35.
go back to reference Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol agosto de. 2005;48(2):252–7.CrossRef Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol agosto de. 2005;48(2):252–7.CrossRef
36.
go back to reference Welz A, Schmeller N, Schmitz C, Reichart B, Hofstetter A. Resection of hypernephromas with vena caval or right atrial tumor extension using extracorporeal circulation and deep hypothermic circulatory arrest: a multidisciplinary approach. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 1997;12(1):127–32.CrossRef Welz A, Schmeller N, Schmitz C, Reichart B, Hofstetter A. Resection of hypernephromas with vena caval or right atrial tumor extension using extracorporeal circulation and deep hypothermic circulatory arrest: a multidisciplinary approach. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 1997;12(1):127–32.CrossRef
37.
go back to reference Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73(1):62–8.PubMedCrossRef Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73(1):62–8.PubMedCrossRef
38.
go back to reference Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Lond Engl. 2016;387(10032):2008–16.CrossRef Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Lond Engl. 2016;387(10032):2008–16.CrossRef
39.
go back to reference Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(35):3916–23.CrossRef Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(35):3916–23.CrossRef
40.
go back to reference Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(12):2371–8.CrossRef Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(12):2371–8.CrossRef
41.
go back to reference Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(34):4064–75.CrossRef Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(34):4064–75.CrossRef
42.
go back to reference Ryan CW, Tangen C, Heath EI, Stein MN, Meng M, Alva AS, et al. EVEREST: Everolimus for renal cancer ensuing surgical therapy—a phase III study (SWOG S0931, NCT01120249). J Clin Oncol. 2022;40(17_suppl):LAB500–5001.CrossRef Ryan CW, Tangen C, Heath EI, Stein MN, Meng M, Alva AS, et al. EVEREST: Everolimus for renal cancer ensuing surgical therapy—a phase III study (SWOG S0931, NCT01120249). J Clin Oncol. 2022;40(17_suppl):LAB500–5001.CrossRef
43.
go back to reference Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–94.PubMedCrossRef Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385(8):683–94.PubMedCrossRef
44.
go back to reference Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.PubMedCrossRef Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.PubMedCrossRef
45.
go back to reference Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.PubMedCrossRef Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.PubMedCrossRef
46.
go back to reference Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRef Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRef
47.
go back to reference Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293–300.PubMedCrossRef Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293–300.PubMedCrossRef
48.
go back to reference Iacovelli R, Nolè F, Verri E, Renne G, Paglino C, Santoni M, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143–8.PubMedCrossRef Iacovelli R, Nolè F, Verri E, Renne G, Paglino C, Santoni M, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143–8.PubMedCrossRef
49.
go back to reference Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, et al. The predictive value of Programmed Death Ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783–92.PubMedCrossRef Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, et al. The predictive value of Programmed Death Ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur Urol. 2021;79(6):783–92.PubMedCrossRef
50.
go back to reference Carretero-González A, Lora D, Martín Sobrino I, Sáenz Sanz I, Bourlon MT, Anido Herranz U, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel). 2020;12(7):1945.PubMedCrossRef Carretero-González A, Lora D, Martín Sobrino I, Sáenz Sanz I, Bourlon MT, Anido Herranz U, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel). 2020;12(7):1945.PubMedCrossRef
51.
go back to reference Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015;21(6):1329–39.PubMedCrossRef Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015;21(6):1329–39.PubMedCrossRef
52.
go back to reference Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612–24.PubMedCrossRef Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):612–24.PubMedCrossRef
53.
go back to reference McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57.PubMedPubMedCentralCrossRef McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57.PubMedPubMedCentralCrossRef
54.
go back to reference Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26(11):1733–41.PubMedPubMedCentralCrossRef Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020;26(11):1733–41.PubMedPubMedCentralCrossRef
55.
go back to reference Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekssev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.PubMedCrossRef Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekssev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.PubMedCrossRef
56.
go back to reference Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10(3): e004316.PubMedPubMedCentralCrossRef Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022;10(3): e004316.PubMedPubMedCentralCrossRef
57.
go back to reference Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–18.PubMedPubMedCentralCrossRef Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–18.PubMedPubMedCentralCrossRef
58.
go back to reference Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon α2b compared with interferon α2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.PubMedCrossRef Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon α2b compared with interferon α2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.PubMedCrossRef
59.
go back to reference Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–9670.PubMedCrossRef Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–9670.PubMedCrossRef
60.
go back to reference Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27.PubMedCrossRef Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27.PubMedCrossRef
61.
go back to reference Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy in metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80(4):417–24.PubMedCrossRef Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy in metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80(4):417–24.PubMedCrossRef
62.
go back to reference Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomised clinical trial. JAMA Oncol. 2019;5:164.PubMedCrossRef Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomised clinical trial. JAMA Oncol. 2019;5:164.PubMedCrossRef
63.
go back to reference Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Database Study. J Clin Oncol. 2016;34(27):3267–75.PubMedPubMedCentralCrossRef Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Database Study. J Clin Oncol. 2016;34(27):3267–75.PubMedPubMedCentralCrossRef
64.
65.
go back to reference Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.PubMedCrossRef Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.PubMedCrossRef
66.
go back to reference McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(1):133–41.CrossRef McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(1):133–41.CrossRef
67.
go back to reference Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRef Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRef
68.
go back to reference Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.PubMedCrossRef Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.PubMedCrossRef
69.
go back to reference Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.PubMedCrossRef Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.PubMedCrossRef
70.
go back to reference Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9.PubMedPubMedCentralCrossRef Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9.PubMedPubMedCentralCrossRef
71.
go back to reference Heng DY, Xie W, Regan MM, Harshnan LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRef Heng DY, Xie W, Regan MM, Harshnan LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRef
72.
go back to reference Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317–24.PubMedPubMedCentralCrossRef Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317–24.PubMedPubMedCentralCrossRef
73.
go back to reference Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(6):591–7.CrossRef Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(6):591–7.CrossRef
74.
go back to reference Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.PubMedCrossRef Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.PubMedCrossRef
75.
go back to reference Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.PubMedPubMedCentralCrossRef Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.PubMedPubMedCentralCrossRef
76.
go back to reference Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38(6_suppl):609–609.CrossRef Tannir NM, McDermott DF, Escudier B, Hammers HJ, Aren OR, Plimack ER, et al. Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38(6_suppl):609–609.CrossRef
77.
go back to reference Rini BI, Powles T, Atkins MB, Escudier B, McDemott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–15.PubMedCrossRef Rini BI, Powles T, Atkins MB, Escudier B, McDemott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–15.PubMedCrossRef
78.
go back to reference Motzer RJ, Powles T, Atkins MB, Escudier B, McDemott DF, Alekseev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.PubMedCrossRef Motzer RJ, Powles T, Atkins MB, Escudier B, McDemott DF, Alekseev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8(2):275–80.PubMedCrossRef
79.
go back to reference Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15.PubMedPubMedCentralCrossRef Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15.PubMedPubMedCentralCrossRef
80.
go back to reference Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;2:1563–73.CrossRef Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;2:1563–73.CrossRef
81.
go back to reference Choueiri TK, Powles T, Burotto M, Escudier M, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–41.PubMedPubMedCentralCrossRef Choueiri TK, Powles T, Burotto M, Escudier M, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–41.PubMedPubMedCentralCrossRef
82.
go back to reference Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;8(384):1289–300.CrossRef Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;8(384):1289–300.CrossRef
83.
go back to reference Choueiri TK, Powles TB, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(suppl_7):S808–69. Choueiri TK, Powles TB, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(suppl_7):S808–69.
84.
go back to reference Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedPubMedCentralCrossRef Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedPubMedCentralCrossRef
85.
go back to reference Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–67.PubMedCrossRef Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–67.PubMedCrossRef
86.
go back to reference Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23.PubMedPubMedCentralCrossRef Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–23.PubMedPubMedCentralCrossRef
87.
go back to reference Choueiri TK, Escudier B, Powles T, Tannir MM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.PubMedCrossRef Choueiri TK, Escudier B, Powles T, Tannir MM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27.PubMedCrossRef
88.
go back to reference Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.PubMedCrossRef Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.PubMedCrossRef
89.
go back to reference Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95–104.PubMedCrossRef Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21(1):95–104.PubMedCrossRef
90.
go back to reference Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, et al. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016;27(7):1304–11.PubMedPubMedCentralCrossRef Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, et al. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016;27(7):1304–11.PubMedPubMedCentralCrossRef
91.
go back to reference Derosa L, Rouche JA, Colomba E, Baciarello G, Routy B, Albiges L, et al. Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic Renal Cell Carcinoma (mRCC): the Gustave Roussy experience. Ann Oncol. 2017;28(suppl_5):v295–329. Derosa L, Rouche JA, Colomba E, Baciarello G, Routy B, Albiges L, et al. Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic Renal Cell Carcinoma (mRCC): the Gustave Roussy experience. Ann Oncol. 2017;28(suppl_5):v295–329.
92.
go back to reference Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33–40.PubMedCrossRef Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019;108:33–40.PubMedCrossRef
93.
go back to reference Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019;114:67–75.PubMedPubMedCentralCrossRef Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019;114:67–75.PubMedPubMedCentralCrossRef
94.
go back to reference Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol. 2019;76(6):861–7.PubMedPubMedCentralCrossRef Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium. Eur Urol. 2019;76(6):861–7.PubMedPubMedCentralCrossRef
95.
go back to reference Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, et al. Real-world clinical outcomes of pazopanib immediately after discontinuation of immunotherapy for advanced renal cell carcinoma. Clin Genitourin Cancer. 2020;18(1):e37–45.PubMedCrossRef Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, et al. Real-world clinical outcomes of pazopanib immediately after discontinuation of immunotherapy for advanced renal cell carcinoma. Clin Genitourin Cancer. 2020;18(1):e37–45.PubMedCrossRef
96.
go back to reference Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, et al. CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clin Genitourin Cancer. 2022;21:S1558-7673(22)00160-4.PubMed Navani V, Wells JC, Boyne DJ, Cheung WY, Brenner DM, McGregor BA, et al. CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clin Genitourin Cancer. 2022;21:S1558-7673(22)00160-4.PubMed
97.
go back to reference Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212–21.PubMedPubMedCentralCrossRef Gan CL, Dudani S, Wells JC, Donskov F, Pal SK, Dizman N, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212–21.PubMedPubMedCentralCrossRef
98.
go back to reference McGregor BA, Lalani AA, Xie W, Steinharter JA, Bakouny ZE, Martini DJ, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020;135:203–10.PubMedCrossRef McGregor BA, Lalani AA, Xie W, Steinharter JA, Bakouny ZE, Martini DJ, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020;135:203–10.PubMedCrossRef
99.
go back to reference Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, et al. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies. Oncologist. 2021;26(6):476–82.PubMedPubMedCentralCrossRef Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, et al. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies. Oncologist. 2021;26(6):476–82.PubMedPubMedCentralCrossRef
100.
go back to reference Graham J, Shah AY, Wells JC, Mckay RR, Vaishampayan U, Hansen A, et al. Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors. Eur Urol Oncol. 2021;4(1):102–11.PubMedCrossRef Graham J, Shah AY, Wells JC, Mckay RR, Vaishampayan U, Hansen A, et al. Outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy after immuno-oncology checkpoint inhibitors. Eur Urol Oncol. 2021;4(1):102–11.PubMedCrossRef
101.
go back to reference Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;119(6):663–9.PubMedPubMedCentralCrossRef Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;119(6):663–9.PubMedPubMedCentralCrossRef
102.
go back to reference Ornstein MC, Pal SK, Wood LS, Torner JM, Hobss BP, Jia XS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019;20(10):1386–94.PubMedCrossRef Ornstein MC, Pal SK, Wood LS, Torner JM, Hobss BP, Jia XS, et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2019;20(10):1386–94.PubMedCrossRef
103.
go back to reference Procopio G, Pircher C, Claps M, Guadalupi V, Mennitto A, Sepe P, et al. A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: the BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36). J Clin Oncol. 2021;39(6_suppl):326–326.CrossRef Procopio G, Pircher C, Claps M, Guadalupi V, Mennitto A, Sepe P, et al. A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: the BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36). J Clin Oncol. 2021;39(6_suppl):326–326.CrossRef
104.
go back to reference Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-del-Muro X, et al. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 2022;7(2): 100463 (Epub 2022 Apr 8).PubMedPubMedCentralCrossRef Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-del-Muro X, et al. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 2022;7(2): 100463 (Epub 2022 Apr 8).PubMedPubMedCentralCrossRef
105.
go back to reference Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ullbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.PubMedCrossRef Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ullbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105.PubMedCrossRef
106.
go back to reference de Velasco G, McKay RR, Lin X, Moreira MB, Simantov R, Choueiri TK. Comprehensive analysis of survival outcomes in non–clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer. 2017;15(6):652-660.e1.PubMedCrossRef de Velasco G, McKay RR, Lin X, Moreira MB, Simantov R, Choueiri TK. Comprehensive analysis of survival outcomes in non–clear cell renal cell carcinoma patients treated in clinical trials. Clin Genitourin Cancer. 2017;15(6):652-660.e1.PubMedCrossRef
107.
go back to reference Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015;67(4):740–9.PubMedCrossRef Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015;67(4):740–9.PubMedCrossRef
108.
go back to reference Heng DYC, Wells JC, Rini BI, Beuselinck B, Lee J-L, Knox JJ, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66(4):704–10.PubMedCrossRef Heng DYC, Wells JC, Rini BI, Beuselinck B, Lee J-L, Knox JJ, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66(4):704–10.PubMedCrossRef
109.
go back to reference Hudes G, Carducci M, Tomczak P, Dutcher J, Fligin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.PubMedCrossRef Hudes G, Carducci M, Tomczak P, Dutcher J, Fligin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.PubMedCrossRef
110.
go back to reference Armstrong AJ, Halabi S, Eisen T, Broderic S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378–88.PubMedPubMedCentralCrossRef Armstrong AJ, Halabi S, Eisen T, Broderic S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378–88.PubMedPubMedCentralCrossRef
111.
go back to reference Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Martin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.PubMedCrossRef Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Martin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.PubMedCrossRef
112.
go back to reference Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff F, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–72.PubMedPubMedCentralCrossRef Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff F, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–72.PubMedPubMedCentralCrossRef
113.
go back to reference Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71:426–36.PubMedCrossRef Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71:426–36.PubMedCrossRef
114.
go back to reference Park I, Lee SH, Lee JL. A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Clin Genitourin Cancer. 2018;16:e997-1002.PubMedCrossRef Park I, Lee SH, Lee JL. A multicenter phase II trial of axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Clin Genitourin Cancer. 2018;16:e997-1002.PubMedCrossRef
115.
go back to reference Jung KS, Lee SJ, Park SH, Lee J-L, Lee S-H, Lim JY, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study. Cancer Res Treat. 2018;50:488–94.PubMedCrossRef Jung KS, Lee SJ, Park SH, Lee J-L, Lee S-H, Lim JY, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study. Cancer Res Treat. 2018;50:488–94.PubMedCrossRef
116.
go back to reference Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, et al. First-line pazopanib in non-clear-cell renal carcinoma: the Italian retrospective multicenter PANORAMA study. Clin Genitourin Cancer. 2017;15:e609–14.PubMedCrossRef Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, et al. First-line pazopanib in non-clear-cell renal carcinoma: the Italian retrospective multicenter PANORAMA study. Clin Genitourin Cancer. 2017;15:e609–14.PubMedCrossRef
117.
go back to reference Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis. Eur J Cancer. 2018;104:188–94.PubMedCrossRef Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis. Eur J Cancer. 2018;104:188–94.PubMedCrossRef
118.
go back to reference Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program. Am J Clin Oncol. 2019;42:42–5.PubMedCrossRef Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program. Am J Clin Oncol. 2019;42:42–5.PubMedCrossRef
119.
go back to reference Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.PubMedCrossRef Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.PubMedCrossRef
121.
go back to reference Vogelzang NJ, McFarlane JJ, Kochenderfer MD, Molina AM, Arrowsmith E, Bauer TM, et al. Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): results from the phase IIIb/IV CheckMate 374 study. J Clin Oncol. 2019;37(7_suppl):562.CrossRef Vogelzang NJ, McFarlane JJ, Kochenderfer MD, Molina AM, Arrowsmith E, Bauer TM, et al. Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): results from the phase IIIb/IV CheckMate 374 study. J Clin Oncol. 2019;37(7_suppl):562.CrossRef
122.
go back to reference De Giorgi U, Cartení G, Giannarelli D, Basso U, Galli L, Cortesi E, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019;123(1):98–105.PubMedCrossRef De Giorgi U, Cartení G, Giannarelli D, Basso U, Galli L, Cortesi E, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019;123(1):98–105.PubMedCrossRef
123.
go back to reference McKay RR, McGregor BA, Gray K, Steinharter JA, Walsh MK, Braun DA, et al. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). J Clin Oncol. 2019;37(7_suppl):548.CrossRef McKay RR, McGregor BA, Gray K, Steinharter JA, Walsh MK, Braun DA, et al. Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). J Clin Oncol. 2019;37(7_suppl):548.CrossRef
124.
go back to reference Suárez Rodríguez C, Larkin J, Patel PM, Pérez-Valderrama B, Rodríguez-Vida A, Glen H, et al. Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. J Clin Oncol. 2021;39(15_suppl): abstr4511.CrossRef Suárez Rodríguez C, Larkin J, Patel PM, Pérez-Valderrama B, Rodríguez-Vida A, Glen H, et al. Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. J Clin Oncol. 2021;39(15_suppl): abstr4511.CrossRef
125.
go back to reference Lee CH, Voss MH, Carlo MS, Chen YB, Zucker M, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(suppl 15): abstr4509.CrossRef Lee CH, Voss MH, Carlo MS, Chen YB, Zucker M, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(suppl 15): abstr4509.CrossRef
126.
go back to reference Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: eCOG 8802. Med Oncol. 2012;29(2):761–7.PubMedCrossRef Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: eCOG 8802. Med Oncol. 2012;29(2):761–7.PubMedCrossRef
127.
go back to reference Escudier B, Droz JB, Rolland F, Gravis G, Beuzeboc P, Chauvet B, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell Carcinoma: a phase II study of the genitourinary group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959–61.PubMedCrossRef Escudier B, Droz JB, Rolland F, Gravis G, Beuzeboc P, Chauvet B, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell Carcinoma: a phase II study of the genitourinary group of the French Federation of Cancer Centers. J Urol. 2002;168(3):959–61.PubMedCrossRef
Metadata
Title
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
Authors
María José Méndez-Vidal
Martin Lázaro Quintela
Nuria Lainez-Milagro
Begoña Perez-Valderrama
Cristina Suárez Rodriguez
José Ángel Arranz Arija
Ignacio Peláez Fernández
Enrique Gallardo Díaz
Julio Lambea Sorrosal
Aránzazu González-del-Alba
Publication date
09-08-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2023
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03276-5

Other articles of this Issue 9/2023

Clinical and Translational Oncology 9/2023 Go to the issue
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version